Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

291 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer.
de Wit R, Stoter G, Sleijfer DT, Neijt JP, ten Bokkel Huinink WW, de Prijck L, Collette L, Sylvester R. de Wit R, et al. Among authors: stoter g. Br J Cancer. 1998 Sep;78(6):828-32. doi: 10.1038/bjc.1998.587. Br J Cancer. 1998. PMID: 9743309 Free PMC article. Clinical Trial.
Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group.
de Wit R, Stoter G, Sleijfer DT, Kaye SB, de Mulder PH, ten Bokkel Huinink WW, Spaander PJ, de Pauw M, Sylvester R. de Wit R, et al. Among authors: stoter g. Br J Cancer. 1995 Jun;71(6):1311-4. doi: 10.1038/bjc.1995.254. Br J Cancer. 1995. PMID: 7540039 Free PMC article. Clinical Trial.
Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.
de Wit R, Sylvester R, Tsitsa C, de Mulder PH, Sleyfer DT, ten Bokkel Huinink WW, Kaye SB, van Oosterom AT, Boven E, Vermeylen K, Stoter G. de Wit R, et al. Among authors: stoter g. Br J Cancer. 1997;75(3):432-5. doi: 10.1038/bjc.1997.71. Br J Cancer. 1997. PMID: 9020492 Free PMC article. Clinical Trial.
Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.
de Wit R, Stoter G, Kaye SB, Sleijfer DT, Jones WG, ten Bokkel Huinink WW, Rea LA, Collette L, Sylvester R. de Wit R, et al. Among authors: stoter g. J Clin Oncol. 1997 May;15(5):1837-43. doi: 10.1200/JCO.1997.15.5.1837. J Clin Oncol. 1997. PMID: 9164193 Clinical Trial.
A phase I/II study of multicyclic dose-intensive chemotherapy supported with G-CSF, or G-CSF and haematopoietic progenitor cells in whole blood, in two consecutive cohorts of patients.
de Wit R, Kruit WH, Lamers CH, van 't Veer MB, Luyten AA, van Beurden V, Harteveld M, Planting AS, Schmitz PI, Stoter G, Bolhuis RL, Verweij J. de Wit R, et al. Among authors: stoter g. Br J Cancer. 1998 Jun;77(12):2363-6. doi: 10.1038/bjc.1998.392. Br J Cancer. 1998. PMID: 9649159 Free PMC article. Clinical Trial.
291 results